AI in Neurology Market to Reach $2.5 Billion by 2030
"Fueled by advances in deep learning, neuroimaging, and intelligent software platforms, AI in neurology is reshaping diagnostics, enhancing surgical safety, and enabling more personalized treatment, driven by the growing global burden of neurological disorders and the urgent need for faster, more precise care."
Boston, Nov. 27, 2025 (GLOBE NEWSWIRE) -- According to the latest study from BCC Research, “AI in Neurology: Global Markets” is estimated to increase from $705.6 million in 2025 to $2.5 billion by the end of 2030, at a compound annual growth rate (CAGR) of 28.9% from 2025 through 2030.
This report offers a comprehensive review of the global market for AI in neurology, highlighting its rapid growth and transformative impact on neurological healthcare. It reveals how AI is revolutionizing diagnostics, treatment planning, and patient monitoring for conditions like Alzheimer’s, Parkinson’s, stroke, and epilepsy. The study analyzes market trends, regional adoption patterns, investment flows, and technological innovations such as neuroimaging, brain-computer interfaces, and wearable devices. It also provides a look at the vendor landscape and also explores companies’ ESG initiatives.
This report is especially relevant now because the AI in neurology market is reaching a critical inflection point. The rising prevalence of neurological disorders, combined with rapid advances in deep learning and neuroimaging, is driving demand for faster and more precise diagnostic and treatment solutions. As aging populations put an increasing burden on healthcare systems and regulatory bodies fast-track approvals for AI tools, early adopters have a unique opportunity to gain a competitive edge in a market expected to grow exponentially over the next decade.
The factors driving the market’s growth include:
Rising Prevalence of Neurological Disorders: Neurological conditions like Alzheimer’s, Parkinson’s, and stroke are increasing globally due to aging populations and lifestyle factors. This growing burden is pushing healthcare systems to adopt AI tools for faster diagnosis, better disease management, and improved patient outcomes.
Demand for Early Diagnosis and Precision Medicine: AI enables earlier and more accurate detection of neurological diseases by analyzing complex data from scans and patient records. It also supports precision medicine by tailoring treatments to individual needs, improving effectiveness and reducing trial-and-error approaches.
Advancements in Neuroimaging and Data Analytics: AI enhances neuroimaging by detecting subtle abnormalities and automating image analysis. Combined with powerful data analytics, it helps uncover new insights into brain disorders, supports clinical decisions, and speeds up research and diagnosis processes.
Request a sample copy of the global market for AI in neurology report.
Report Synopsis
| Report Metric | Details |
| Base year considered | 2024 |
| Forecast period considered | 2025-2030 |
| Base year market size | $563.6 million |
| Market size forecast | $2.5 billion |
| Growth rate | CAGR of 28.9% for the forecast period of 2025-2030 |
| Segments covered | Product Type, Application, Technology, End User |
| Regions covered | North America, Europe, Asia-Pacific, South America, Middle East and Africa |
| Countries covered | U.S., Canada, Mexico, U.K., Italy, France, Germany, Spain, the Netherlands, Poland, the Czech Republic, Hungary, Austria, Slovakia, Slovenia, China, India, Japan, South Korea, Thailand, Singapore, Taiwan, Vietnam |
| Market Drivers |
|
Interesting fact:
- AI algorithms can now detect early signs of neurological disorders like Alzheimer’s years before symptoms appear, using subtle changes in brain scans or speech patterns, offering a powerful tool for early diagnosis and intervention.
- Brain computer interface projects like Neuralink are emerging to restore movement or communication in paralyzed patients, blurring the line between medical treatment and human machine integration.
The report addresses the following questions:
- What factors are driving the growth of the market?
- The AI in neurology market is fueled by rising neurological disorders, growing demand for early diagnosis and precision medicine, rapid advances in neuroimaging and data analytics, and strong government and regulatory support.
- What are the challenges and opportunities of the market?
- Key challenges include workforce shortages in rural areas and low- to middle-income countries (LMICs), the high cost of AI integration, and lack of standardized validation and transparency in AI-based neurology tools.
- What market segments are covered in the report?
- The market is segmented based on product type, application, technology, end user and region. Products include AI in neuro-oncology and neuroinflammatory disorders, AI in neurovascular and traumatic brain injury, AI in epilepsy and functional brain disorders, AI in spinal and movement disorders, and AI in neurodevelopmental and psychiatric conditions. Applications include neuroimaging analysis, electroencephalography (EEG) interpretation, clinical decision support, drug discovery and development, and other emerging uses. Technologies include machine learning and deep learning, natural language processing (NLP), and other AI approaches. End users include into hospitals and clinics, diagnostic centers, and R&D centers. Regions include North America, Europe, Asia-Pacific, and the Rest of the World (RoW).
- Which type segment will be dominant through 2030?
- Neuroimaging analysis will be the dominant type in the AI in neurology market.
- Which region has the largest market share?
- North America accounted for 47.2% of the market in 2024.
Market leaders include:
- ACTIV SURGICAL
- AIRAMED GMBH
- BRAINOMIX
- BRAINQ TECHNOLOGIES LTD.
- CANON INC.
- GE HEALTHCARE
- KONINKLIJKE PHILIPS N.V.
- MEDTRONIC
- NEOSOMA INC.
- NEURALINK
- NEUROX
- NVIDIA CORP.
- QURE.AI
- SIEMENS HEALTHINEERS AG
- VIZ.AI INC.
Related reports:
Neurology Market: A BCC Research Overview: This report provides a comprehensive analysis of the global neurology therapeutics market, highlighting current trends and future projections. It segments the market by major neurological disorders such as Parkinson’s, Alzheimer’s, epilepsy, psychosis, autism, multiple sclerosis, and brain tumors and further breaks down each by drug class and treatment type. The study explores market drivers, challenges, regulatory landscape, epidemiology, and competitive dynamics including mergers and acquisitions. Regional insights across North America, Europe, Asia Pacific, and the Rest of the World.
Purchase a copy of the report direct from BCC Research.
For further information on any of these reports or to make a purchase, contact info@bccresearch.com.
About BCC Research
BCC Research market research reports provide objective, unbiased measurement and assessment of market opportunities. Our experienced industry analysts' goal is to help you make informed business decisions free of noise and hype.
For media inquiries, email press@bccresearch.com or visit our media page for access to our market research library.
Any data and analysis extracted from this press release must be accompanied by a statement identifying BCC Research LLC as the source and publisher.

BCC Research Corporate HQ: 50 Milk St., Ste. 16, Boston, MA 02109, U.S. Email: info@bccresearch.com Phone: +1 781-489-7301
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.